|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
61,398,000 |
Market
Cap: |
291.03(M) |
Last
Volume: |
320,189 |
Avg
Vol: |
710,310 |
52
Week Range: |
$3.38 - $6.5 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Vanda Pharmaceuticals is a biopharmaceutical company. Co.'s commercial portfolio is comprised of two products, HETLIOZ® for the treatment of Non-24 Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome and Fanapt® for the treatment of schizophrenia. In addition, Co. has a number of drugs in development, including: Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; and VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
2,251 |
2,251 |
123,349 |
363,323 |
Total Sell Value |
$13,327 |
$13,327 |
$526,672 |
$2,473,859 |
Total People Sold |
1 |
1 |
5 |
6 |
Total Sell Transactions |
1 |
1 |
11 |
29 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Wijkstrom Joakim |
SVP, Chief Marketing Officer |
|
2024-03-05 |
4 |
S |
$4.21 |
$38,830 |
D/D |
(9,229) |
129,789 |
|
-50% |
|
Moran Kevin Patrick |
SVP, CFO & Treasurer |
|
2024-03-05 |
4 |
S |
$4.20 |
$37,411 |
D/D |
(8,902) |
231,014 |
|
-50% |
|
Birznieks Gunther |
SVP, Business Development |
|
2024-03-05 |
4 |
S |
$4.13 |
$35,884 |
D/D |
(8,684) |
313,569 |
|
-50% |
|
Williams Timothy |
SVP & General Counsel |
|
2024-03-05 |
4 |
S |
$4.18 |
$37,396 |
D/D |
(8,941) |
196,825 |
|
-50% |
|
Polymeropoulos Mihael Hristos |
President and CEOChairman of t |
|
2024-03-05 |
4 |
S |
$4.13 |
$100,273 |
D/D |
(24,288) |
1,871,730 |
|
-50% |
|
Wijkstrom Joakim |
SVP, Chief Marketing Officer |
|
2024-03-04 |
4 |
S |
$4.41 |
$33,091 |
D/D |
(7,498) |
139,018 |
|
-41% |
|
Moran Kevin Patrick |
SVP, CFO & Treasurer |
|
2024-03-04 |
4 |
S |
$4.48 |
$25,982 |
D/D |
(5,798) |
239,916 |
|
-41% |
|
Birznieks Gunther |
SVP, Business Development |
|
2024-03-04 |
4 |
S |
$4.30 |
$37,495 |
D/D |
(8,727) |
322,253 |
|
-41% |
|
Williams Timothy |
SVP & General Counsel |
|
2024-03-04 |
4 |
S |
$4.41 |
$35,917 |
D/D |
(8,147) |
205,766 |
|
-41% |
|
Polymeropoulos Mihael Hristos |
President and CEOChairman of t |
|
2024-03-04 |
4 |
S |
$4.24 |
$131,066 |
D/D |
(30,884) |
1,896,018 |
|
-41% |
|
Williams Timothy |
SVP & General Counsel |
|
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
213,913 |
|
- |
|
Wijkstrom Joakim |
SVP, Chief Marketing Officer |
|
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
32,700 |
146,516 |
|
- |
|
Moran Kevin Patrick |
SVP, CFO & Treasurer |
|
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
245,714 |
|
- |
|
Polymeropoulos Mihael Hristos |
President and CEOChairman of t |
|
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
450,000 |
1,926,902 |
|
- |
|
Birznieks Gunther |
SVP, Business Development |
|
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
330,980 |
|
- |
|
Wijkstrom Joakim |
SVP, Chief Marketing Officer |
|
2023-08-21 |
4 |
S |
$5.84 |
$21,748 |
D/D |
(3,724) |
113,816 |
|
28% |
|
Mitchell Stephen Ray |
Director |
|
2023-08-10 |
4 |
S |
$6.05 |
$39,349 |
D/D |
(6,500) |
29,328 |
|
36% |
|
Moran Kevin Patrick |
SVP, CFO & Treasurer |
|
2023-07-28 |
4 |
S |
$6.30 |
$13,945 |
D/D |
(2,212) |
120,714 |
|
33% |
|
Williams Timothy |
SVP & General Counsel |
|
2023-06-13 |
4 |
S |
$6.56 |
$95,754 |
D/D |
(14,600) |
88,913 |
|
34% |
|
Honore Tage |
Director |
|
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
17,307 |
43,715 |
|
- |
|
Dugan Richard W |
Director |
|
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
17,307 |
97,700 |
|
- |
|
Chrousos Phaedra |
Director |
|
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
17,307 |
42,238 |
|
- |
|
Ward Anne Sempowski |
Director |
|
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
17,307 |
39,313 |
|
- |
|
Mitchell Stephen Ray |
Director |
|
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
17,307 |
35,828 |
|
- |
|
Honore Tage |
Director |
|
2023-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
26,408 |
26,408 |
|
- |
|
272 Records found
|
|
Page 1 of 11 |
|
|